United States, Georgia, Blue Ridge – 08-13-2020 (PRDistribution.com) — Blue Ridge, GA.–(PR Distribution)—Faith Springs, LLC, a health company has filed a pre-Investigational New Drug (pIND) request with the Food and Drug Administration for a new compound for the treatment of COVID-19 in humans. On June 10, 2020, the National Institutes of Health notified Faith Springs that it welcomed summary of available data on its compound including its mechanisms of action, associated clinical trials, safety data, and scalability.
On July 24, 2020, the company filed an Emergency Use Authorization request to allow for its compound to be sold while it gathers further evidence to support the safe use of this compound. Faith Springs looks forward to moving its compound through the FDA regulatory process and hopefully to approval. About Faith SpringsFaith Springs, LLC is a privately held health company that manufacturers and develops various products. The company uses a proprietary process to manufacture and enhance the in vitro efficacy of its products and is continuing to explore therapeutic areas where lowing oxidative stress can prove beneficial.For more information please visit: www.h2forlife.com.Forward-Looking StatementsThis press release may contain forward-looking statements, about Faith Springs expectations, beliefs or intentions regarding, among other things, market risks and uncertainties, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Faith Springs or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Faith Springs with press releases or oral statements made by or with the approval of one of Faith Springs’s authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Faith Springs’s actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Faith Springs’s actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the impact of the recent outbreak of coronavirus; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry. Faith Springs does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise. ContactsDanny Day
Chief Executive Officer
For the original news story, please visit https://prdistribution.com/news/faith-springs-files-nih-and-fda-filings-for-covid-19-treatment-2.html.